HAISCO PHARMACEUTICAL GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.28 CNY | +1.41% |
|
+0.33% | +17.84% |
| Apr. 19 | Haisco Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 18 | Haisco Pharmaceutical Gets Nod to Trial HSK16149 Capsules | MT |
Business Summary
Number of employees: 5,448
Sales per Business
| CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Anesthesia
25.3
%
| 437 | 14.5 % | 850 | 25.3 % | +94.35% |
Parenteral Nutrition
18.3
%
| 641 | 21.3 % | 615 | 18.3 % | -4.09% |
Raw Materials
17.0
%
| - | - | 570 | 17.0 % | - |
Other
12.6
%
| 372 | 12.3 % | 422 | 12.6 % | +13.25% |
Services
12.3
%
| - | - | 414 | 12.3 % | - |
Tumor Antiemetic
6.3
%
| 266 | 8.8 % | 212 | 6.3 % | -20.34% |
Antibiotics
3.5
%
| 98 | 3.3 % | 119 | 3.5 % | +21.13% |
Cardiovascular and Cerebrovascular
2.0
%
| 89 | 3.0 % | 67 | 2.0 % | -24.55% |
Hepatobiliary Digestion
2.0
%
| 66 | 2.2 % | 67 | 2.0 % | +1.81% |
Other Business
0.6
%
| 17 | 0.6 % | 20 | 0.6 % | +17.06% |
Sales per region
| CNY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
China
100.0
%
| 3,015 | 100.0 % | 3,355 | 100.0 % | +11.27% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Xiu Lian Fan
CEO | Chief Executive Officer | 61 | 06-12-31 |
Peng Duan
DFI | Director of Finance/CFO | 49 | 16-10-20 |
Jun Min Wang
CHM | Chairman | 56 | 06-12-31 |
Wei Zheng
BRD | Director/Board Member | 54 | 06-12-31 |
Yan Guo
IRC | Investor Relations Contact | - | - |
Meng Wang
SEC | Corporate Secretary | 39 | 11-01-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jun Min Wang
CHM | Chairman | 56 | 06-12-31 |
Wei Zheng
BRD | Director/Board Member | 54 | 06-12-31 |
Xiu Lian Fan
CEO | Chief Executive Officer | 61 | 06-12-31 |
Chuan De Cao
BRD | Director/Board Member | 60 | 23-08-24 |
Jun Le
BRD | Director/Board Member | 53 | 20-05-19 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 1,114,117,970 | 227,401,303 ( 20.41 %) | 14,393,330 ( 1.292 %) | 20.41 % |
Company contact information
Haisco Pharmaceutical Group Co., Ltd.
17 Sanxiang Avenue Zedang Town
856000, Shannan
+86 89 3783 4865
http://www.haisco.com
Sector
Sales per Business
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
27.28
Average target price
-
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.84% | 4.15B | |
| +23.48% | 562B | |
| -5.45% | 358B | |
| +20.85% | 322B | |
| +8.88% | 297B | |
| +13.25% | 219B | |
| +6.63% | 199B | |
| -10.10% | 196B | |
| -8.93% | 149B | |
| -5.12% | 146B |
- Stock Market
- Equities
- 002653 Stock
- Company Haisco Pharmaceutical Group Co., Ltd.
